Immunotherapy and Targeted Therapies in NSCLC: Phase 3 Data From ESMO 2022
Results from 4 trials presented at ESMO 2022 highlight the efficacy of immunotherapy and targeted therapies in non-small cell lung cancer.
Source: cancertherapyadvisor.com
Page 40 - Ming Lee News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Ming Lee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Ming Lee Today - Breaking & Trending Today
First-Line Atezolizumab Outperforms Chemo in Poor-Prognosis Non-Small Cell Lung Cancer
First-line atezolizumab improves overall survival, compared with chemotherapy, in patients with poor-prognosis non-small cell lung cancer.
Source: oncologynurseadvisor.com
Atezolizumab Doubles Survival of NSCLC Patients With Poor PS
Patients with untreated NSCLC who could not withstand the rigors of platinum-based chemotherapy regimens had much better overall survival when treated with the immune checkpoint inhibitor atezolizumab.
Source: medscape.com
Best iPhone Game Updates: 'PUBG Mobile', 'Honkai Impact 3rd', 'Jetpack Joyride 2', 'Merge Mansion', and More – TouchArcade
Hello everyone, and welcome to the week! It's time once again for our look back at the noteworthy updates of the last seven days. This last week has felt like a year for me, but I'm back in the saddle now and ready to settle back into my routine.
Source: toucharcade.com
First-Line Atezolizumab Outperforms Chemo in Poor-Prognosis Non-Small Cell Lung Cancer
First-line atezolizumab improves overall survival, compared with chemotherapy, in patients with poor-prognosis non-small cell lung cancer.
Source: cancertherapyadvisor.com